Effect of carboplatin when administered after dacarbazine failure: Clinical benefit of sequential therapy

Dacarbazine chemotherapy has been the mainstay of melanoma treatment for >30 years. In the early 2000s, carboplatin (with or without other agents, such as paclitaxel) was the most commonly used second‑line therapy in the UK. The aim of the present study was to report a significant response rate to second‑line carboplatin in patients from three UK institutions who had been previously treated and failed to respond to dacarbazine, and investigate whether sequential therapy may be more effective compared with combination therapy. A total of 104 patients were identified, the majority of whom were treated with carboplatin (area under the curve 5‑6) every 3 weeks for a maximum of 6 cycles. A total of 102 patients were evaluable for response, among whom 11 patients had an objective response (1 complete response and 10 partial responses) and 15 had stable disease, giving an overall response rate of 11% and disease control rate of 26%. The median progression‑free survival was 1.8 months (range, 0.2‑36+ months) and the median overall survival was 4.6 months (range, 0.2‑36+ months). Surprisingly, the majority of the patients who benefited from second‑line carboplatin therapy were those with visceral metastases, the survival of whom would not be expected to exceed 6 months after first‑line treatment